On October 6, 2024 Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, reported that the first patient has been dosed in a Phase 1 investigator-sponsored study of BTX-A51 at Dana-Farber Cancer Institute (Press release, Edgewood Oncology, OCT 6, 2024, View Source [SID1234651961]). The trial is evaluating BTX-A51 in patients with metastatic and/or recurrent liposarcoma, which is characterized by Murine Double Minute Clone 2 (MDM2) amplifications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BTX-A51 is a multi-specific kinase inhibitor targeting casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9)—key regulators of transcriptional control and tumor cell survival.

The ongoing Phase 1 study is a single-arm pilot trial designed to assess the safety and tolerability of BTX-A51, along with an initial evaluation of its biological activity in patients with advanced MDM2-amplified liposarcoma. The trial is currently open for enrollment. Additional details about the study can be found at clinicaltrials.gov under the identifier NCT06414434.